TA-8995 clinical trials
Also written Obicetrapib and TA-8995.
How each study uses TA-8995 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the TA-8995 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
27 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 3 |
| 2024 | 5 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 27 · Other 0
NewAmsterdam Pharma (19) · Xention Ltd (6) · Mitsubishi Tanabe Pharma Corporation (2)
Often tested with
Tested in the same studies.
Ezetimibe (3) · Multimodality Therapy (1) · Atorvastatin (1) · Rosuvastatin (1) · Drospirenone (1) · Ethinyl Estradiol (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 2 in phase 3
Studies that test TA-8995, phase 3 first.
- Nov 2026Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular DiseasePhase 3 · NewAmsterdam Pharma
- Nov 2027A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary PlaquePhase 3 · NewAmsterdam Pharma
- Nov 2026Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) LevelsPhase 2 · NewAmsterdam Pharma
Studies
Open first, then newest update. How each study uses TA-8995 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 27
- Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's DiseaseRecruitingPhase 2NewAmsterdam PharmaNCT07794670Written as Obicetrapib 10 mg
- Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) LevelsRecruitingPhase 2NewAmsterdam PharmaNCT06496243Written as obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
- Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy VolunteersRecruitingPhase 2NewAmsterdam PharmaNCT06982508Written as Obicetrapib 10mg
- A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic SyndromeActive, not recruitingPhase 3NewAmsterdam PharmaNCT07219602Written as obicetrapib 10 mg + ezetimibe 10 mg FDC daily
- A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary PlaqueActive, not recruitingPhase 3NewAmsterdam PharmaNCT06305559Written as obicetrapib 10 mg + ezetimibe 10 mg FDC daily
- Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying TherapiesCompletedPhase 3NewAmsterdam PharmaNCT06005597Written as Monotherapy obicetrapib
- Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying TherapiesCompletedPhase 3NewAmsterdam PharmaNCT05142722Written as Obicetrapib
- Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.CompletedPhase 3NewAmsterdam PharmaNCT05425745Written as Obicetrapib
- A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and RosuvastatinCompletedPhase 1NewAmsterdam PharmaNCT06081166Written as Obicetrapib
- Proof-of-concept, Open-label Study in Patients With Early Alzheimer's DiseaseCompletedPhase 2NewAmsterdam PharmaNCT05161715Written as Obicetrapib
- A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult SubjectsCompletedPhase 1NewAmsterdam PharmaNCT06547359Written as Obicetrapib 10mg
- A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.CompletedPhase 2NewAmsterdam PharmaNCT05421078Written as Obicetrapib
- Investigating the Effect of Obicetrapib on Lipoprotein MetabolismActive, not recruitingPhase 1NewAmsterdam PharmaNCT05972278Written as Obicetrapib
- PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic FunctionCompletedPhase 1NewAmsterdam PharmaNCT06048302Written as Obicetrapib
- Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without ObicetrapibCompletedPhase 1NewAmsterdam PharmaNCT06250205Written as Obicetrapib
- Randomized Study of Obicetrapib as an Adjunct to Statin TherapyCompletedPhase 2NewAmsterdam PharmaNCT04753606Written as Obicetrapib
- Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS TherapyCompletedPhase 2NewAmsterdam PharmaNCT05266586Written as Obicetrapib
- Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular DiseaseActive, not recruitingPhase 3NewAmsterdam PharmaNCT05202509Written as Obicetrapib
- Randomized Study of Obicetrapib in Combination With EzetimibeCompletedPhase 2NewAmsterdam PharmaNCT04770389Written as Obicetrapib 5mg
- ADME Study in Healthy Male Subjects With TA-8995CompletedPhase 1Xention LtdNCT02408055Written as TA-8995